Neuroprotection Is Unlikely to Be Effective in Humans Using Current Trial Designs
- 1 January 2002
- journal article
- editorial
- Published by Wolters Kluwer Health in Stroke
- Vol. 33 (1) , 306-307
- https://doi.org/10.1161/str.33.1.306
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Combination Therapy Stroke Trial: Recombinant Tissue-Type Plasminogen Activator with/without LubeluzoleCerebrovascular Diseases, 2001
- Intravenous Ancrod for Treatment of Acute Ischemic StrokeJAMA, 2000
- Intra-arterial Prourokinase for Acute Ischemic StrokeJAMA, 1999
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995
- Intravenous Thrombolysis With Recombinant Tissue Plasminogen Activator for Acute Hemispheric StrokeJAMA, 1995